Regulatory
Breakthrough Device Designation(BDD)
In one line
FDA program providing expedited review for devices that treat life-threatening or irreversibly debilitating conditions.
Definition
The Breakthrough Devices Program offers more interactive FDA communication, sprint discussions, and prioritized review for devices that provide more effective treatment or diagnosis of serious conditions and meet at least one additional criterion such as no approved alternatives.
Designation is requested through a Q-Submission and does not lower the evidence standard for marketing authorization. Beyond priority review, it may support certain CMS coverage pathways.
Why it matters
Designation does not change the evidentiary standard for clearance or approval but typically shortens timelines and improves alignment. Breakthrough status can also support Medicare reimbursement under the TCET pathway.
Common pitfalls
- •One common mistake is assuming that Breakthrough Device Designation lowers the evidentiary standards for marketing authorization, which it does not.
- •Another pitfall is delaying engagement with the FDA until late in device development, missing opportunities for early feedback and program benefits.
- •Misunderstanding the criteria for designation, particularly the "no approved or cleared alternatives" clause, can lead to wasted application efforts.
- •Failing to maintain the breakthrough characteristics throughout the development process can result in loss of designation.
- •Companies sometimes incorrectly believe that breakthrough designation guarantees Medicare reimbursement, rather than merely facilitating a pathway like TCET, which still requires its own application and review.
Sources
- Breakthrough Devices Program · FDA
- European Commission - Medical Devices · European Commission
- IMDRF Documents · IMDRF